Military.com By Nick Mordowanec 4/19/2026
President Donald Trump’s latest executive order to accelerate medical treatments for serious mental illness, notably psychedelics, was described by one advocate to Military.com as “a turning point” for the military veteran community.
Trump’s executive order signed on Saturday calls on the U.S. Food and Drug Administration (FDA) to facilitate access to psychedelic drugs, including ibogaine compounds, psilocybin, ketamine, LSD and MDMA, for eligible patients suffering from major depressive disorder and substance abuse disorders. Trump and U.S. Health Secretary Robert F. Kennedy, Jr. said newer methods have become necessary beyond reliance on prescription medicines.
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said Saturday in the Oval Office, joined by others including RFK Jr. and podcast host Joe Rogan, the latter of whom Trump said had sent “some information” to the president about such treatments.
The order could set a new standard for how drugs under the Schedule I banner of the Controlled Substances Act could be reclassified pending successful trials by medical professionals.
Psilocybin, for example, has long been known as the main ingredient in “magic mushrooms.” The U.S. Drug Enforcement Administration describes that and Ibogaine, both currently Schedule I drugs among others, as having "no currently accepted medical use and a high potential for abuse.”
Trump’s executive order also calls on the Department of Health and Human Services to allocate at least $50 million from existing funds to support and partner with state governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses, including through federal funding, technical assistance and data sharing.
More:
https://www.military.com/daily-news/2026/04/18/ibogaine-lsd-and-psilocybin-trumps-new-order-medical-turning-point.html
